Compare AESI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | STOK |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2023 | 2019 |
| Metric | AESI | STOK |
|---|---|---|
| Price | $13.59 | $32.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $11.49 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 3.1M | 699.1K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,095,310,000.00 | $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.55 | $82.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.73 | ★ 404.50 |
| 52 Week Low | $7.64 | $5.35 |
| 52 Week High | $19.00 | $40.22 |
| Indicator | AESI | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 43.79 |
| Support Level | $13.07 | $31.60 |
| Resistance Level | $14.65 | $35.75 |
| Average True Range (ATR) | 0.77 | 2.35 |
| MACD | 0.09 | -0.51 |
| Stochastic Oscillator | 85.08 | 21.03 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.